scholarly journals Intravitreal ranibizumab for diabetic macular edema patients with good baseline visual acuity; a real life study

2017 ◽  
Author(s):  
Abdullah Özkaya
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Intravitreal Ranibizumab ◽  
Life Study ◽  
Real Life Study ◽  
Baseline Visual Acuity

scholarly journals Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies

2018 ◽  
Vol 2018 ◽  
pp. 1-16 ◽  
Author(s):  
Laurent Kodjikian ◽  
David Bellocq ◽  
Thibaud Mathis
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Observational Studies ◽  
Real Life ◽  
Pharmacological Management ◽  
Anti Vegf ◽  
Pubmed Database ◽  
Baseline Visual Acuity

Objectives of the Study. Summary of observational studies concerning the pharmacological management of diabetic macular edema (DME). Methods. A literature review was conducted using the PubMed database on 1 February 2018 to identify studies evaluating the efficacy of anti-VEGF and dexamethasone (DEX) implants for DME. Studies with more than 10 patients and follow-up of more than 6 months were selected. Analyses were carried out on the overall population and on subgroups defined according to baseline visual acuity (BVA) and the patients’ naïve or non-naïve status. Results. Thirty-two studies evaluating the efficacy of anti-VEGF and 31 studies evaluating the efficacy of DEX-implants were retained, concerning 6,842 and 1,703 eyes, respectively. A mean gain of +4.7 letters for a mean of 5.8 injections (mean follow-up: 15.6 months) and +9.6 letters for a mean of 1.6 injections (10.3 months) was found in the anti-VEGF and DEX-implant studies, respectively. Final VA appears to be similar for both treatment (62 letters for anti-VEGF, 61.2 letters for DEX-implant), and BVA appears lower for DEX-implant, which may partially explain the greater visual gain. The DEX-implant studies show greater gains in VA compared to the anti-VEGF studies, especially for higher BVA. Indeed, mean gains for the subgroups of patients with BVA<50 letters, 50<BVA<60 letters, and BVA>60 letters are +4.3, +5.8, and +3.1 letters, respectively, in the anti-VEGF studies and +10.5, +9.3, and +8.8 letters, respectively, in the DEX-implant studies. Regarding the patient’s initial status, only naïve status appears to confer the best functional response in DEX-implant studies. Conclusion. Observational studies investigating DEX-implant report clinically similar final VA when compared to anti-VEGF, but superior visual gains in real-life practice. This latter difference could be due to the better BVA, but also to the fact that less injections were administered in the anti-VEGF observational studies than in the interventional studies.

Efficacy and safety of ranibizumab in diabetic macular edema: real life study

2015 ◽  
Vol 93 ◽  
pp. n/a-n/a
Author(s):  
L. Hrarat ◽  
F. Fajnkuchen ◽  
V. Sarda ◽  
T. Grenet ◽  
S. Buffet ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Efficacy And Safety ◽  
Life Study ◽  
Real Life Study

REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT

Retina ◽  
2017 ◽  
Vol 37 (4) ◽  
pp. 753-760 ◽  
Author(s):  
Ariane Malclès ◽  
Corinne Dot ◽  
Nicolas Voirin ◽  
Émilie Agard ◽  
Anne-Laure Vié ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Dexamethasone Implant ◽  
Life Study ◽  
Real Life Study

Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study

2020 ◽  
Vol 57 (12) ◽  
pp. 1413-1421 ◽  
Author(s):  
Thibaud Mathis ◽  
Théo Lereuil ◽  
Amro Abukashabah ◽  
Nicolas Voirin ◽  
Aditya Sudhalkar ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Dexamethasone Implant ◽  
Life Study ◽  
Long Term Follow Up ◽  
Real Life Study

scholarly journals The Effects of Epiretinal Membranes on the Treatment Outcomes of Dexamethasone Implants in Diabetic Macular Edema: A Real-Life Study

2020 ◽  
Vol 36 (5) ◽  
pp. 298-303
Author(s):  
Burak Erden ◽  
Akın Çakır ◽  
Selim Bölükbaşı ◽  
Şeyma Gülcenur Özturan ◽  
Mustafa Nuri Elçioğlu
Keyword(s):  
Macular Edema ◽  
Treatment Outcomes ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Epiretinal Membranes ◽  
Life Study ◽  
Real Life Study

scholarly journals Diabetic Macular Edema Patients with Poor Baseline Visual Acuity Treated with Ranibizumab in Real Life and Optical Coherence Tomography Based Predictor Factors for Visual Outcomes

2018 ◽  
Vol 08 (02) ◽  
pp. 008-014
Author(s):  
Abdullah Ozkaya ◽  
Mehmet Ozveren ◽  
Okkes Baz ◽  
Hatice Nur Tarakcioglu ◽  
Korhan Fazil ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Real Life ◽  
Life Outcomes ◽  
Stable Vision ◽  
The Mean ◽  
Baseline Visual Acuity

Abstract Purpose: We aimed to evaluate the real life outcomes of ranibizumab in the treatment of diabetic macular edema (DME) patients with a baseline visual acuity<0.05 in decimals. Methods: Newly diagnosed DME patients with a visual acuity ≤0.05, treated with ranibizumab monotherapy, and completed a follow-up time of 12 months were included retrospectively. Patients were evaluated in regards to change in best corrected visual acuity (BCVA) and central retinal thickness, and the total visit and injection numbers. Results: A total of 24 eyes of 24 patients were included. Mean BCVA at baseline, month 3, 6, 9, and 12 was, 0.04±0.01, 0.12±0.12, 0.12±0.11, 0.17±0.19, and 0.21±0.21 (p<0.05 for all), respectively. One eye (4.2%) had VA loss of ≥3 lines, and six eyes (25.0%) had stable vision (loss of <3 line, or remained stable, or gained <1 lines), and 17 eyes (70.8%) had VA gain of ≥3 lines at month 12.The mean visit number at month 12 was 4.8±1 and the mean injection number was 4.0 ±1.4. Conclusion: Ranibizumab seemed to be effective in the treatment of DME patients with a low visual acuity in real life.

scholarly journals Three Year Outcomes of Intravitreal Ranibizumab and Aflibercept Treatment of Patients with Diabetic Macular Edema in a Real-World Setting

2021 ◽  
Author(s):  
Yusuf Berk Akbaş ◽  
Cengiz Alagöz ◽  
Semih Çakmak ◽  
Gökhan Demir ◽  
Neşe Alagöz ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Intravitreal Ranibizumab ◽  
Life Study ◽  
Corrected Visual Acuity ◽  
Real World Setting ◽  
Change In Mean ◽  
Anatomical Outcomes

Abstract PurposeTo evaluate and compare the functional and anatomical outcomes of intravitreal ranibizumab (IVR) and aflibercept (IVA) treatments in patients with diabetic macular edema (DME).MethodsFour hundred three eyes of 235 naïve patients who underwent IVR or IVA treatment for diabetic macular edema and followed up to 36 months included in this retrospective, real-life study. All patients underwent 3 loading doses and followed up with a PRN regimen. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline, year 1, 2 and 3. ResultsThere were 198 eyes in IVR group and 205 eyes in IVA group. The changes in mean BCVA were 0.09±0.32 vs 0.17±0.41 logMAR (p=0.042) at year 1, 0.09±0.37 vs 0.12±0.45 logMAR (p=0.512) at year 2 and 0.13± 0.36 vs 0.15±0.48 logMAR (p=0.824) at year 3 in IVA and IVR groups, respectively. The baseline mean BCVA were lower (p=0.004) in IVA group. In terms of CMT changes, there were no differences between groups. ConclusionAt year 1, change in mean BCVA was statistically significantly higher in IVA group, however this difference did not persist at year 2 and 3. Both ranibizumab and aflibercept treatments achieved a good long-term visual and anatomical response in DME patients.

Sign in / Sign up

Export Citation Format

Share Document